Tracers / [225Ac]Ac-hu5A10
[225Ac]Ac-hu5A10
Also written as [Ac-225]hu5A10
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Humanized monoclonal antibody (IgG1)
- Target / mechanism
- Targets free PSA (KLK3) PMID 33441295
- Clinical application
- Radioimmunotherapy of prostate cancer using alpha-emitting 225Ac-labeled anti-PSA antibody PMID 33441295
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | hu5A10 DiaProst AB / Innovagen AB | 33441295 2021 Clin Cancer Res The hu5A10 radio-immunoconstructs were prepared according to previously published protocols unique to the specific radionuclide (see supplementary methods). |
Need this precursor?We can point you to suppliers for [225Ac]Ac-hu5A10, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33441295. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33441295: 'Humanized 5A10 IgG1 mAb was developed by DiaProst AB (Lund, Sweden) and produced by Innovagen AB (Lund, Sweden)'.